Calls for papers
-
InCarda Therapeutics has announced the initiation of the Phase 3 RESTORE-1 trial of its InRhythm flecainide inhalation solution in patients with new or recurrent atrial fibrillation. According to InCarda, the FDA has agreed that the… Read more . . .
-
Hailie inhaler monitoring system maker Adherium announced that the FDA has cleared the company’s new version of the Hailie sensor for use with Ellipta dry powder inhalers. Adherium submitted the 510(k) application to the FDA… Read more . . .
-
Revelation Biosciences announced that the Phase 1b CLEAR challenge study of its REVTx-99b intranasal phosphorylated hexaacylated disaccharide (PHAD) in participants with allergies to rye grass pollen showed that the nasal drops were safe and well… Read more . . .
-
ARS Pharmaceuticals plans to merge with Silverback Therapeutics, the companies said, with the combined company focused on approval and launch of ARS’s Neffy (ARS-1) epinephrine nasal spray for the treatment of allergic reactions. Shareholders of… Read more . . .
-
VistaGen Therapeutics said that the PALISADE-1 Phase 3 clinical trial of PH94B aloradine nasal spray for the treatment of anxiety in social anxiety disorder failed to meet its primary endpoint. The company announced the initiation… Read more . . .
-
CyanVac subsidiary Blue Lake Biotechnology said that dosing has begun in a Phase 1 clinical trial of the company’s BLB-201 intranasal vaccine against respiratory syncytial virus. The open label trial is expected to enroll 15… Read more . . .
-
OINDP characterization specialist Proveris Scientific announced that former Proveris Associate Product Manager Alyssa Rubino has rejoined the company as a Technical Data Scientist at Proveris Laboratories. Rubino, who was most recently Medical and Dental Product… Read more . . .
-
SoftOx Solutions has announced that the European Defense Fund has awarded a 3-year grant of approximately NOK 97 million (~€9.6 million) to the company’s subsidiary SoftOx Defense Solutions (SDS) for development of an inhalation solution… Read more . . .
-
According to Liquidia, the US Patent Trial and Appeal Board (PTAB) has found that none of the claims included in US Patent No. 10,716,793, covering Tyvaso inhaled treprostinil, are valid. The company said that the PTAB ruling would have… Read more . . .
-
Impel Pharmaceuticals said that it has initiated a Phase 2a study of its INP105 intranasal olanzapine in adolescents with autism spectrum disorder, with results expected early next year. In January 2019, Impel (then Impel Neuropharma)… Read more . . .
Upcoming Events
Sponsored by Intertek
Want information about upcoming OINDP-related events delivered directly to your inbox? click here
September 15-September 18: DDL New Researcher Network Summer Event, London, UK
September 16-September 17: IPAC-RS 2026 Nasal Innovation Forum, Jersey City, NJ, USA
September 24-September 25: Inhaled & Nasal Biologics | DNA Forum, Cambridge, UK
October 14-October 15: Advancing Bioequivalence Frameworks for Inhalation and Nasal Drug Products: Optimizing In Vitro, In Vivo, and In Silico Methods, Rockville, MD, USA
October 19-October 20: MVIC Autumn Training 2026, Lund, Sweden